Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective.

ABSTRACT:

SUBMITTER: Triebwasser MP 

PROVIDER: S-EPMC9269994 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature